CELLDEX THERAPEUTICS INC (CLDX)
Health Care · Clinical-stage monoclonal and bispecific antibody therapeutics for inflammatory and immune-mediated diseases · NASDAQ
A clinical-stage biopharmaceutical company developing mast cell-targeted monoclonal and bispecific antibodies for chronic urticaria, inflammatory skin diseases, and systemic inflammatory conditions.
What CELLDEX THERAPEUTICS INC does
Celldex Therapeutics is a biopharmaceutical company focused on developing monoclonal and bispecific antibodies that target mast cell biology to treat severe inflammatory, allergic, autoimmune, and other diseases. The company's lead program, barzolvolimab (CDX-0159), is a KIT receptor antagonist in Phase 3 development for chronic spontaneous urticaria, cold urticaria, symptomatic dermographism, prurigo nodolaris, and atopic dermatitis. Celldex is also advancing its next-generation bispecific antibody platform, including CDX-622 targeting TSLP and SCF for inflammatory diseases.
Themes: ["Mast cell biology / targeted immunotherapy","Chronic urticaria / rare inflammatory skin diseases","Therapeutic antibodies","Autoimmune and allergic disease treatment"]
Fundamentals
- Price$38.98 as of 2026-07-09 close
- Market cap$3.0B as of 2026-07-10
- 1-year return+73.6% as of 2026-07-09 close
- Net margin-25011.8% as of 2026-07-10
- Gross margin+17.6% as of 2026-07-10
- ROE-50.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-88.5% as of 2026-07-10
- Revenue CAGR (3y)-13.1% SEC XBRL
- Beta0.81 as of 2026-07-10
Key risks (from latest filing)
["Company has no approved products and significant operating losses; success depends entirely on regulatory approval and commercial success of drug candidates in development.","Rapid cash burn ($65.6M operating cash used in Q1 2026) against dwindling revenue; the company must maintain sufficient capital to fund development through potential approvals.","Clinical development timelines carry risk of failure or delay; Phase 3 data for barzolvolimab (lead asset in CSU) expected Q4 2026."]
Competitors & peers
- Kalvista Pharmaceuticals
- Faes Pharma
- Novartis (NVS)
- Regeneron Pharmaceuticals (REGN)
- Genmab
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.